Pfizer and biontech provide update on omicron variant.

New york & mainz, germany--(business wire)--pfizer inc. (nyse: pfe) and biontech se (nasdaq: bntx) today announced results from an initial laboratory study demonstrating that serum antibodies induced by the pfizer-biontech covid-19 vaccine (bnt162b2) neutralize the sars-cov-2 omicron variant after three doses. sera obtained from vaccinees one month after receiving the booster vaccination (third dose of bnt162b2 vaccine) neutralized the omicron variant to levels that are comparable to those obse
BNTX Ratings Summary
BNTX Quant Ranking